{
    "ticker": "SLDB",
    "name": "Solid Biosciences Inc.",
    "description": "Solid Biosciences Inc. is a biotechnology company focused on advancing the development of innovative therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder characterized by progressive muscle degeneration. Founded in 2013, Solid Biosciences aims to create meaningful treatments for patients with DMD through its proprietary gene therapy platform. The company is committed to addressing the unmet needs of the DMD community by utilizing cutting-edge science and technology to develop its drug candidates. Solid's lead product candidate, SGT-001, is designed to deliver a functional copy of the dystrophin gene, which is crucial for muscle function. The company engages closely with the DMD community to ensure that its research is aligned with the needs and aspirations of patients and their families. Solid Biosciences also emphasizes collaboration with academic and industry partners to accelerate the path to effective treatments. The company is dedicated to transparency and communication, sharing its research progress with stakeholders and fostering a supportive environment for patients.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2013",
    "website": "https://www.solidbio.com",
    "ceo": "Ilan Ganot",
    "social_media": {
        "twitter": "https://twitter.com/SolidBio",
        "linkedin": "https://www.linkedin.com/company/solid-biosciences"
    },
    "investor_relations": "https://investors.solidbio.com",
    "key_executives": [
        {
            "name": "Ilan Ganot",
            "position": "CEO"
        },
        {
            "name": "Mark E. Schmidt",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapy",
            "products": [
                "SGT-001"
            ]
        }
    ],
    "seo": {
        "meta_title": "Solid Biosciences Inc. | Advancing Gene Therapies for DMD",
        "meta_description": "Solid Biosciences Inc. is dedicated to developing innovative therapies for Duchenne muscular dystrophy, focusing on gene therapy solutions. Learn more about our mission and product pipeline.",
        "keywords": [
            "Solid Biosciences",
            "Duchenne Muscular Dystrophy",
            "Gene Therapy",
            "Biotechnology",
            "SGT-001"
        ]
    },
    "faq": [
        {
            "question": "What is Solid Biosciences focused on?",
            "answer": "Solid Biosciences is focused on developing therapies for Duchenne muscular dystrophy (DMD)."
        },
        {
            "question": "What is SGT-001?",
            "answer": "SGT-001 is Solid Biosciences' lead gene therapy product candidate for treating DMD."
        },
        {
            "question": "Where is Solid Biosciences headquartered?",
            "answer": "Solid Biosciences is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "When was Solid Biosciences founded?",
            "answer": "Solid Biosciences was founded in 2013."
        }
    ],
    "competitors": [
        "SRPT",
        "PTCT",
        "BMRN"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "AMGN",
        "REGN"
    ]
}